Halozyme Therapeutics (HALO) stock
Halozyme Therapeutics is a growth company in the “Health care” sector. Here are the key numbers from official filings and the price. The full report with 20 years of history, comparison and news is in the Analyst.
| Metric | Value | Verdict |
|---|---|---|
| Revenue growth a year | 28.5% | fast |
| Profit margin | 22.7% | high |
| Debt to annual profit | 4.3 | high |
| Dividends a year | — | does not pay |
| Price to earnings (P/E) | 42 | expensive |
| Share price over the year | +69% | rose |
The full report: 20 years of history, valuation, comparison with any companies, news and a live price.
Open the HALO report →In short
Of five key metrics, 2 are strong and 2 weak. Over the past year the stock rose (+69%).
Which goal it fits
- Grow capital — partly.
- Earn income — does not fit.
- Preserve — partly.
Assessed by the same rules as in the Analyst: the company's metrics are checked against what matters for each goal.
Does Halozyme Therapeutics pay dividends
No, Halozyme Therapeutics does not pay dividends now — profit stays in the company.
Is Halozyme Therapeutics stock expensive
Price to earnings (P/E) is 42: an investor pays 42 dollars for each dollar of the company's annual profit. That is expensive: future growth is already priced in.
Other companies in the sector
ELI Lilly AND Company · Johnson & Johnson · AbbVie · Merck · Astrazeneca · Amgen · Gilead Sciences · Abbott Laboratories · Novo Nordisk A/S · Pfizer
Worth reading
How to pick a stock: five metrics · What an ETF is in plain words · How to start investing from zero
Data as of 2026-10-06: filings — SEC EDGAR, price — Yahoo Finance. This page is educational and is not investment advice.